Skip to Content

Arduan (pipecuronium) Disease Interactions

There are 5 disease interactions with Arduan (pipecuronium):

Major

Neuromuscular blocking agents (Includes Arduan) ↔ liver disease

Severe Potential Hazard, High plausibility. Applies to: Liver Disease

Neuromuscular blocking agents undergo metabolism by the liver. Elimination and effects may be prolonged in patients with liver disease. Therapy with neuromuscular blocking agents should be administered cautiously in patients with liver disease.

References

  1. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  2. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  3. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  4. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
  5. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 5 references
Major

Neuromuscular blocking agents (Includes Arduan) ↔ paresis

Severe Potential Hazard, High plausibility. Applies to: Paralytic Disorder

Patients with hemiparesis or paraparesis may require higher dosages of non-depolarizing neuromuscular blocking agents in the affected limbs. Neuromuscular monitoring should be performed on a non-paretic limb to avoid inaccurate dosing.

References

  1. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  2. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  4. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
  5. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  6. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 6 references
Major

Neuromuscular blocking agents (Includes Arduan) ↔ pulmonary impair

Severe Potential Hazard, High plausibility. Applies to: Pulmonary Impairment

Neuromuscular blocking agents can cause respiratory depression and paralysis. Therapy with neuromuscular blocking agents should be administered cautiously in patients with pulmonary impairment. Treatment of respiratory paralysis consists of positive-pressure artificial respiration with oxygen and maintenance of a patent airway until the recovery of normal respiration is assured.

References

  1. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  2. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
  3. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  4. "Product Information. Anectine (succinylcholine)." Glaxo Wellcome, Research Triangle Park, NC.
  5. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
  6. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  7. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
View all 7 references
Moderate

Neuromuscular blocking agents (Includes Arduan) ↔ obesity

Moderate Potential Hazard, High plausibility. Applies to: Obesity

A few of the neuromuscular blocking agents, including doxacurium, mivacurium and pipecuronium, may have prolonged and/or enhanced effects in obese patients (i.e. weight >= 30% over ideal body weight for height). Dosing of these agents should be based on ideal body weight in obese patients.

References

  1. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
Moderate

Neuromuscular blocking agents (Includes Arduan) ↔ renal dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Renal Dysfunction

Many of the non-depolarizing (competitive) neuromuscular blocking agents undergo significant elimination by the kidney. Their effects may, therefore, be prolonged in patients with renal dysfunction. Therapy with these neuromuscular blocking agents should be administered cautiously and initiated at reduced dosages in renally compromised patients, depending on the level of insufficiency. If possible, alternative agents should be considered. Atracurium, rocuronium and vecuronium do not depend on kidney function for clearance and are often the non-depolarizing muscle relaxants of choice in renal failure.

References

  1. "Product Information. Anectine (succinylcholine)." Glaxo Wellcome, Research Triangle Park, NC.
  2. "Product Information. Nuromax (doxacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  3. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  4. "Product Information. Mivacron (mivacurium)." Glaxo Wellcome, Research Triangle Park, NC.
  5. "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.
  6. "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
  7. "Product Information. Metubine Iodide (metocurine)." Dista Products Company, Indianapolis, IN.
  8. "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.
View all 8 references

Arduan (pipecuronium) drug interactions

There are 137 drug interactions with Arduan (pipecuronium)

Arduan (pipecuronium) alcohol/food interactions

There is 1 alcohol/food interaction with Arduan (pipecuronium)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide